Clinical trials in acute respiratory distress syndrome: challenges and opportunities

The Lancet Respiratory Medicine

Volumn 5, Issue 6, 2017, Pages 524-534

  Matthay, Michael A ^a   McAuley, Daniel F ^b   Ware, Lorraine B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; BUDESONIDE PLUS SALMETEROL; DEXAMETHASONE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPERTENSIVE FACTOR; KETOCONAZOLE; LIPOSOMAL PROSTAGLANDIN; LISOFYLLINE; METHYLPREDNISOLONE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; OMEGA 3 FATTY ACID; PARACETAMOL; PROSTAGLANDIN; ROSUVASTATIN; SIMVASTATIN; SIVELESTAT; SURFACTANT; UNCLASSIFIED DRUG; VALGANCICLOVIR; VITAMIN D;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BONE MARROW CELL; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; EMERGENCY CARE; ENDOTRACHEAL INTUBATION; EXTRACORPOREAL CARBON DIOXIDE REMOVAL; EXTRACORPOREAL OXYGENATION; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; LUNG FUNCTION; LUNG INFILTRATE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MORTALITY; NONHUMAN; OXYGEN TENSION; OXYGENATION; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RE EVALUATION OF SYSTEMIC EARLY NEUROMUSCULAR BLOCKADE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SHOCK; SOCIAL SUPPORT; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TIDAL VOLUME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; X-RAY COMPUTED TOMOGRAPHY; DISEASE EXACERBATION; METHODOLOGY; OBSERVATIONAL STUDY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85019746232     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30188-1     Document Type: Review

References (100)

1. Ashbaugh, DG, Bigelow, DB, Petty, TL, Levine, BE, Acute respiratory distress in adults. Lancet 290 (1967), 319–323.
2. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 (2000), 1301–1308.
3. Wiedemann, HP, Wheeler, AP, Bernard, GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354 (2006), 2564–2575.
4. Boyle, AJ, Mac Sweeney, R, McAuley, DF, Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med, 11, 2013, 166.
5. Ware, LB, Matthay, MA, Medical progress: the acute respiratory distress syndrome. N Engl J Med 342 (2000), 1334–1349.
6. Matthay, MA, Ware, LB, Zimmerman, GA, The acute respiratory distress syndrome. J Clin Invest 122 (2012), 2731–2740.
7. Murray, JF, Matthay, MA, Luce, JM, Flick, MR, An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138 (1988), 720–723.
8. Bernard, GR, Artigas, A, Brigham, KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (1994), 818–824.
9. Ranieri, VM, Rubenfeld, GD, Thompson, BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307 (2012), 2526–2533.
10. Papazian, L, Forel, JM, Gacouin, A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 363 (2010), 1107–1116.
11. Guervilly, C, Bisbal, M, Forel, JM, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med 43 (2017), 408–418.
12. Gainnier, M, Roch, A, Forel, JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 32 (2004), 113–119.
13. Guerin, C, Reignier, J, Richard, JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 368 (2013), 2159–2168.
14. Gattinoni, L, Taccone, P, Carlesso, E, Marini, JJ, Prone position in acute respiratory distress syndrome. Rationale, indications, and limits. Am J Respir Crit Care Med 188 (2013), 1286–1293.
15. Brower, RG, Lanken, PN, MacIntyre, N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351 (2004), 327–336.
16. Mercat, A, Richard, JC, Vielle, B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299 (2008), 646–655.
17. Meade, MO, Cook, DJ, Guyatt, GH, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299 (2008), 637–645.
18. Antonelli, M, Conti, G, Esquinas, A, et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med 35 (2007), 18–25.
19. Janz, DR, Bastarache, JA, Peterson, JF, et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med 41 (2013), 784–790.
20. Shaver, CM, Upchurch, CP, Janz, DR, et al. Cell-free hemoglobin: a novel mediator of acute lung injury. Am J Physiol Lung Cell Mol Physiol 310 (2016), L532–L541.
21. Boutaud, O, Moore, KP, Reeder, BJ, et al. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci USA 107 (2010), 2699–2704.
22. Janz, DR, Bastarache, JA, Rice, TW, et al. Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis trial. Crit Care Med 43 (2015), 534–541.
23. Bernard, GR, Luce, JM, Sprung, CL, High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317 (1987), 1565–1570.
24. Meduri, GU, Headley, AS, Golden, E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280 (1998), 159–165.
25. Steinberg, KP, Hudson, LD, Goodman, RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354 (2006), 1671–1684.
26. Taylor, RW, Zimmerman, JL, Dellinger, RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 291 (2004), 1603–1609.
27. Spragg, RG, Lewis, JF, Walmarath, H-D, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 351 (2004), 884–892.
28. Willson, DF, Truwit, JD, Conaway, MR, Traul, CS, Egan, EE, The adult calfactant in acute respiratory distress syndrome trial. Chest 148 (2015), 356–364.
29. Matthay, MA, Brower, RG, Carson, S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 184 (2011), 561–568.
30. Gao Smith, F, Perkins, GD, Gates, S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 379 (2012), 229–235.
31. McAuley, DF, Laffey, JG, O'Kane, CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371 (2014), 1695–1703.
32. National Heart Lung Blood Institute ARDS Clinical Trials Network, Truwit, JD, Bernard, GR, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370 (2014), 2191–2200.
33. Bernard, GR, Wheeler, AP, Arons, MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 112 (1997), 164–172.
34. The Acute Respiratory Distress Syndrome Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 283 (2000), 1995–2002.
35. The Acute Respiratory Distress Syndrome Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 30 (2002), 1–6.
36. Rice, TW, Wheeler, AP, Thompson, BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 306 (2011), 1574–1581.
37. Liu, KD, Levitt, J, Zhuo, H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 178 (2008), 618–623.
38. Abraham, E, Baughman, R, Fletcher, E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 27 (1999), 1478–1485.
39. Paine, R 3rd, Standiford, TJ, Dechert, RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40 (2012), 90–97.
40. Zeiher, BG, Artigas, A, Vincent, JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 32 (2004), 1695–1702.
41. Vincent, JL, Artigas, A, Petersen, LC, Meyer, C, A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 37 (2009), 1874–1880.
42. Adhikari, NK, Burns, KE, Friedrich, JO, Granton, JT, Cook, DJ, Meade, MO, Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ, 334, 2007, 779.
43. Hallman, M, Merritt, TA, Jarvenpaa, AL, et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 106 (1985), 963–969.
44. Shapiro, DL, Notter, RH, Morin, FC 3rd, et al. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76 (1985), 593–599.
45. Gotts, JE, Matthay, MA, Sepsis: pathophysiology and clinical management. BMJ, 353, 2016, i1585.
46. Gajic, O, Dabbagh, O, Park, PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 183 (2011), 462–470.
47. Neto, AS, Barbas, CS, Simonis, FD, et al. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med 4 (2016), 882–893.
48. Kor, DJ, Carter, RE, Park, PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA 315 (2016), 2406–2414.
49. Bellani, G, Laffey, JG, Pham, T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315 (2016), 788–800.
50. Rubenfeld, GD, Who cares about preventing acute respiratory distress syndrome?. Am J Respir Crit Care Med 191 (2015), 255–260.
51. Wang, CY, Calfee, CS, Paul, DW, et al. One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. Intensive Care Med 40 (2014), 388–396.
52. Matthay, MA, Pati, S, Lee, JW, Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis. Stem Cells 35 (2017), 316–324.
53. Silversides, JA, Major, E, Ferguson, AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 43 (2017), 155–170.
54. Levitt, JE, Bedi, H, Calfee, CS, Gould, MK, Matthay, MA, Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure. Chest 135 (2009), 936–943.
55. Levitt, JE, Calfee, CS, Goldstein, BA, Vojnik, R, Matthay, MA, Early acute lung injury: criteria for identifying lung injury prior to the need for positive pressure ventilation. Crit Care Med 41 (2013), 1929–1937.
56. Flori, HR, Glidden, DV, Rutherford, GW, Matthay, MA, Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 171 (2004), 995–1001.
57. Kangelaris, KN, Ware, LB, Wang, CY, et al. Timing of intubation and clinical outcomes in adults with acute respiratory distress syndrome. Crit Care Med 44 (2016), 120–129.
58. Frat, JP, Thille, AW, Mercat, A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372 (2015), 2185–2196.
59. Festic, E, Carr, GE, Cartin-Ceba, R, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med 45 (2017), 798–805.
60. Matthay, MA, Beitler, JR, Clinical, Radiographic, physiologic, and biologic measurements to facilitate personalized medicine for ARDS. Chest 150 (2016), 989–990.
61. Calfee, CS, Delucchi, K, Parsons, PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2 (2014), 611–620.
62. Famous, KR, Delucchi, K, Ware, LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195 (2017), 331–338.
63. Gattinoni, L, Tognoni, G, Pesenti, A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 345 (2001), 568–573.
64. Taccone, P, Pesenti, A, Latini, R, et al. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 302 (2009), 1977–1984.
65. Mancebo, J, Fernandez, R, Blanch, L, et al. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med 173 (2006), 1233–1239.
66. Guerin, C, Gaillard, S, Lemasson, S, et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 292 (2004), 2379–2387.
67. Gattinoni, L, Carlesso, E, Taccone, P, Polli, F, Guerin, C, Mancebo, J, Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient meta-analysis. Minerva Anestesiol 76 (2010), 448–454.
68. Nuckton, TJ, Alonso, JA, Kallet, RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 346 (2002), 1281–1286.
69. Kallet, RH, Zhuo, H, Liu, KD, et al. The association between physiologic dead-space fraction and mortality in subjects with ARDS enrolled in a prospective multi-center clinical trial. Respir Care 59 (2014), 1611–1618.
70. Gattinoni, L, Caironi, P, Cressoni, M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 354 (2006), 1775–1786.
71. Beitler, JR, Majumdar, R, Hubmayr, RD, et al. Volume delivered during recruitment maneuver predicts lung stress in acute respiratory distress syndrome. Crit Care Med 44 (2016), 91–99.
72. Vieillard-Baron, A, Girou, E, Valente, E, et al. Predictors of mortality in acute respiratory distress syndrome. Focus on the role of right heart catheterization. Am J Respir Crit Care Med 161 (2000), 1597–1601.
73. Zeyed, YF, Bastarache, JA, Matthay, MA, Ware, LB, The severity of shock is associated with impaired rates of net alveolar fluid clearance in clinical acute lung injury. Am J Physiol Lung Cell Mol Physiol 303 (2012), L550–L555.
74. Rouby, JJ, Puybasset, L, Cluzel, P, Richecoeur, J, Lu, Q, Grenier, P, Regional distribution of gas and tissue in acute respiratory distress syndrome. II. Physiological correlations and definition of an ARDS severity score. CT Scan ARDS Study Group. Intensive Care Med 26 (2000), 1046–1056.
75. Mrozek, S, Jabaudon, M, Jaber, S, et al. Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study. Chest 150 (2016), 998–1007.
76. Warren, MA, Bastarache, JA, Shaver, CM, et al. The RALE score for radiographic assessment of lung edema: association with clinical outcomes and response to conservative fluid treatment in ARDS. Am J Respir Crit Care Med, 2017 in press.
77. Calfee, CS, Eisner, MD, Ware, LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 35 (2007), 2243–2250.
78. Luo, L, Shaver, CM, Zhao, Z, et al. Clinical predictors of hospital mortality differ between direct and indirect acute respiratory distress syndrome. Chest 151 (2017), 755–763.
79. Calfee, CS, Janz, DR, Bernard, GR, et al. Distinct molecular phenotypes of direct versus indirect ARDS in single and multi-center studies. Chest 147 (2015), 1539–1548.
80. Pelosi, P, Caironi, P, Gattinoni, L, Pulmonary and extrapulmonary forms of acute respiratory distress syndrome. Semin Respir Crit Care Med 22 (2001), 259–268.
81. Shaver, CM, Bastarache, JA, Clinical and biological heterogeneity in acute respiratory distress syndrome: direct versus indirect lung injury. Clin Chest Med 35 (2014), 639–653.
82. Meyer, NJ, Calfee, CS, Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. Lancet Respir Med 5 (2017), 524–534.
83. Wilson, JG, Liu, KD, Zhuo, H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3 (2015), 24–32.
84. Liu, KD, Wilson, JG, Zhuo, H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care, 4, 2014, 22.
85. Brower, RG, Shanholtz, CB, Fessler, HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 27 (1999), 1492–1498.
86. Herridge, MS, Moss, M, Hough, CL, et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med 42 (2016), 725–738.
87. Blackwood, B, Clarke, M, McAuley, DF, McGuigan, PJ, Marshall, JC, Rose, L, How outcomes are defined in clinical trials of mechanically ventilated adults and children. Am J Respir Crit Care Med 189 (2014), 886–893.
88. Huang, DT, Angus, DC, Moss, M, et al. Design and rationale of the reevaluation of systemic early neuromuscular blockade trial for acute respiratory distress syndrome. Ann Am Thorac Soc 14 (2017), 124–133.
89. Prescott, HC, Calfee, CS, Thompson, BT, Angus, DC, Liu, VX, Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194 (2016), 147–155.
90. Ware, LB, Koyama, T, Billheimer, DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137 (2010), 288–296.
91. Iwashyna, TJ, Burke, JF, Sussman, JB, Prescott, HC, Hayward, RA, Angus, DC, Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. Am J Respir Crit Care Med 192 (2015), 1045–1051.
92. Berry, DA, Bayesian clinical trials. Nat Rev Drug Discov 5 (2006), 27–36.
93. Lipsky, AM, Lewis, RJ, Response-adaptive decision-theoretic trial design: operating characteristics and ethics. Stat Med 32 (2013), 3752–3765.
94. The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 (2000), 1301–1308.
95. Wheeler, AP, Bernard, GR, Thompson, BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354 (2006), 2213–2224.
96. Walter, J, Ware, LB, Matthay, MA, Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2 (2014), 1016–1026.
97. Hough, CL, Steroids for acute respiratory distress syndrome?. Clin Chest Med 35 (2014), 781–795.
98. Yadav, H, Kor, DJ, Platelets in the pathogenesis of acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 309 (2015), L915–L923.
99. Chen, W, Janz, DR, Bastarache, JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med 43 (2015), 801–807.
100. Boyle, AJ, Di Gangi, S, Hamid, UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care, 19, 2015, 109.